TSE:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free CRDL Stock Alerts C$2.44 -0.03 (-1.21%) (As of 04/22/2024 ET) Add Compare Share Share Today's RangeC$2.35▼C$2.5850-Day RangeC$1.36▼C$2.8352-Week RangeC$0.74▼C$2.94Volume68,966 shsAverage Volume137,742 shsMarket CapitalizationC$158.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlines Get Cardiol Therapeutics alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Cardiol Therapeutics Stock (TSE:CRDL)Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.Read More CRDL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRDL Stock News HeadlinesApril 23, 2024 | americanbankingnews.comCardiol Therapeutics' (CRDL) Buy Rating Reaffirmed at HC WainwrightApril 20, 2024 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc Purchase WT up on Tuesday (CRDL-WT-A)April 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 17, 2024 | americanbankingnews.comCardiol Therapeutics (TSE:CRDL) Stock Price Down 2%April 13, 2024 | seekingalpha.comCRDL:CA Cardiol Therapeutics Inc.February 21, 2024 | finance.yahoo.comCardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent PericarditisFebruary 9, 2024 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Monday (CRDL-WT-A)February 2, 2024 | finance.yahoo.comIs Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?April 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...January 30, 2024 | morningstar.comCardiol Therapeutics Inc Class ADecember 5, 2023 | finance.yahoo.comCardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-PilotNovember 1, 2023 | proactiveinvestors.comCardiol Therapeutics reaches new milestone in Phase II study for recurrent pericarditisNovember 1, 2023 | finance.yahoo.comCardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent PericarditisOctober 23, 2023 | finanznachrichten.deCardiol Therapeutics Inc.: Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementOctober 13, 2023 | finance.yahoo.comCardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart DiseasesOctober 13, 2023 | finance.yahoo.comCardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart DiseasesOctober 11, 2023 | proactiveinvestors.comCardiol Therapeutics releases positive study results of...Cardiol Therapeutics releases positive study results of...October 10, 2023 | benzinga.comCBD To Treat Heart Failure? New Study Shows Its Cardioprotective EffectsSeptember 28, 2023 | finanznachrichten.deCardiol Therapeutics Inc.: Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare ConferenceSeptember 26, 2023 | finance.yahoo.comCardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare ConferenceSeptember 19, 2023 | proactiveinvestors.comCardiol Therapeutics on track to complete enrollment for acute myocarditis trial six months ahead of scheduleAugust 16, 2023 | msn.comCardiol Therapeutics Inc. (CRDL) Upgraded to Buy: Here's What You Should KnowJune 6, 2023 | finance.yahoo.comCRDL.TO - Cardiol Therapeutics Inc.May 19, 2023 | investing.comCardiol Therapeutics (CRDL) Earnings Dates & ReportsMay 9, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc down on Monday (CRDL)April 21, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc up on Friday (CRDL)April 12, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc up on Tuesday (CRDL)See More Headlines Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/22/2024Next Earnings (Estimated)5/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CRDL CUSIPN/A CIKN/A Webwww.cardiolrx.com Phone289 910 0850FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-28,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.88% Return on Assets-34.61% Debt Debt-to-Equity Ratio0.52 Current Ratio5.29 Quick Ratio6.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$2.49 per share Price / Cash Flow0.98 Book ValueC$0.54 per share Price / Book4.52Miscellaneous Outstanding Shares65,110,000Free FloatN/AMarket CapC$158.87 million OptionableNot Optionable Beta0.75 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. David G. Elsley MBAPresident, CEO & DirectorMr. Christopher J. Waddick C.A.C.M.A., CPA, CMA, MBA, CFO, Corporate Secretary & DirectorMr. Bernard Lim B.Sc.Chief Operating OfficerDr. Andrew Warwick Hamer M.D. (Age 62)Chief Medical Officer & Head of Research & Development Comp: $746.56kTrevor BurnsInvestor RelationsKey CompetitorsHLS TherapeuticsTSE:HLSMedexus PharmaceuticalsCVE:MDPLeaf MobileTSE:LEAFRIV CapitalTSE:RIVCipher PharmaceuticalsTSE:CPHView All Competitors CRDL Stock Analysis - Frequently Asked Questions Should I buy or sell Cardiol Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CRDL shares. View CRDL analyst ratings or view top-rated stocks. How have CRDL shares performed in 2024? Cardiol Therapeutics' stock was trading at C$1.10 at the beginning of the year. Since then, CRDL shares have increased by 121.8% and is now trading at C$2.44. View the best growth stocks for 2024 here. When is Cardiol Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024. View our CRDL earnings forecast. How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:CRDL) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
